XYLOCAINE (lidocaine) by AstraZeneca is clinical pharmacology mechanism of action: lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Approved for pain, local anesthesia, regional anesthesia and 1 more indications. First approved in 1964.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
XYLOCAINE (lidocaine) is a local anesthetic that stabilizes neuronal membranes by inhibiting ionic fluxes required for impulse initiation and conduction. Formulated as a rectal suppository, it provides topical anesthesia with onset of action in 3-5 minutes. It is used for local anesthetic indications where rectal administration is appropriate.
Product is approaching loss of exclusivity with moderate competitive pressure (30), signaling a transition toward generic competition and potential team right-sizing.
CLINICAL PHARMACOLOGY Mechanism of action: Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Onset of anesthesia: Lidocaine Ointment 5% effects local, topical anesthesia. The…
Worked on XYLOCAINE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Lidocaine for LESS Postoperative Shoulder Pain Alleviation
A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine
A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants
Efficacy and Safety of Stellate Ganglion Block With Lidocaine Combined Platelet-rich Plasma to Treat Chronic Migraine
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on XYLOCAINE offers limited growth opportunity given its mature lifecycle stage and approaching loss of exclusivity. Career roles focus on defending market share, managing generic transition, and operational efficiency rather than innovation or expansion.